The trajectory of Viagra presents a challenging picture for investors. While the initial introduction generated significant gains, the lapse of its exclusive rights opened the floodgates to cheaper versions, dramatically eroding sales. This creates a specific challenge for firms relying on related blockbuster offerings, suggesting that a unquestion

The legacy of Viagra, and its developer copyright, presents a complex case study for investors. At first a blockbuster drug, producing billions in income, its exclusivity period created a flood of knock-off medications, significantly diminishing its dominance. While specific businesses may attempt to capitalize on related treatments , the current l